Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock closed at 147.5 per share at the end of the most recent trading day (a 0.82% change compared to the prior day closing price) with a volume of 1.53M shares and market capitalization of 17.82B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1453 people. Alnylam Pharmaceuticals Inc. CEO is John M. Maraganore.

The one-year performance of Alnylam Pharmaceuticals Inc. stock is -15.76%, while year-to-date (YTD) performance is -13.02%. ALNY stock has a five-year performance of 73.1%. Its 52-week range is between 117.58 and 212, which gives ALNY stock a 52-week price range ratio of 31.69%

Alnylam Pharmaceuticals Inc. currently has a PE ratio of -18.30, a price-to-book (PB) ratio of 41.29, a price-to-sale (PS) ratio of 18.82, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.70%, a ROC of -56.48% and a ROE of -134.53%. The company’s profit margin is -97.99%, its EBITDA margin is -74.20%, and its revenue ttm is $879.98 Million , which makes it $7.28 revenue per share.

Of the last four earnings reports from Alnylam Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.63 for the next earnings report. Alnylam Pharmaceuticals Inc.’s next earnings report date is 02nd Aug 2022.

The consensus rating of Wall Street analysts for Alnylam Pharmaceuticals Inc. is Strong Buy (1.5), with a target price of $212.33, which is +43.95% compared to the current price. The earnings rating for Alnylam Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alnylam Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alnylam Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.27, ATR14 : 6.06, CCI20 : 176.23, Chaikin Money Flow : 0.26, MACD : 2.27, Money Flow Index : 73.47, ROC : 10.07, RSI : 64.47, STOCH (14,3) : 97.08, STOCH RSI : 1.00, UO : 71.92, Williams %R : -2.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alnylam Pharmaceuticals Inc. in the last 12-months were: Akshay K. Vaishnaw (Option Excercise at a value of $682 542), Akshay K. Vaishnaw (Sold 13 423 shares of value $2 661 443 ), John M. Maraganore (Option Excercise at a value of $882 324), John M. Maraganore (Sold 67 957 shares of value $12 615 995 ), Laurie B. Keating (Option Excercise at a value of $1 488 270), Laurie B. Keating (Sold 16 812 shares of value $3 108 598 ), Steven M. Paul (Option Excercise at a value of $169 950), Steven M. Paul (Sold 15 000 shares of value $2 560 371 ), Tolga Tanguler (Option Excercise at a value of $0), Yvonne Greenstreet (Option Excercise at a value of $4 091 234), Yvonne Greenstreet (Sold 53 064 shares of value $10 559 736 ), Yvonne L Greenstreet (Option Excercise at a value of $4 091 234), Yvonne L Greenstreet (Sold 53 064 shares of value $10 559 736 )